Regeneron Pharmaceuticals, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (68)

Latest Posts

About This Stock More About This Stock
10 Stocks Powering S&P 500 ETF In The 10-Year Bull Run
Article By: Sweta Killa
Wednesday, March 13, 2019 2:36 PM EDT
Though most of the stocks in the fund’s portfolio have delivered astounding returns during the decade, a few were the real stars, skyrocketing more than 2000%. Here are the 10 best-performing stocks in the SPY ETF over the past decade:
In this article: NFLX, ABMD, ULTA, URI, INCY, ALGN, REGN, WCG, AMZN, BKNG
Read
Biotech Bonanza: 2019 Outlook
Article By: Tarun Chandra, CFA
Tuesday, January 1, 2019 1:04 PM EDT
In 2019 biotech stocks will have an uphill battle, but will still provide opportunities for attractive gains.
In this article: IBB, SPY, XBI, XLV, MRNA, TSRO Also: AGN, BMY, JNJ, MRK, NVS, PFE, AMGN, LLY, AZN, GSK, ALXN, REGN, CVS, ESRX, VRTX
Read
Morning Call For Friday, Dec. 14
Article By: Jim Van Meerten
Friday, December 14, 2018 7:46 AM EDT
Mar E-mini S&Ps (ESH19 -0.91%) this morning are down -0.80% and European stocks are down -0.87% on global growth concerns.
In this article: ALV, PG, UHS, REGN, ADBE, COST, SPX, TNX, WBA
Read
HH Biotech Bear Market: But Is It Time To Start Trading?
Article By: Rod Raynovich
Sunday, November 11, 2018 11:31 PM EDT
The Nasdaq is down 1.6% and the Russell 2000 is down 1.8%, killing hopes of a continued Post-Election rally. The biotech sector is for experienced traders only. Healthcare still looks good overall with the XLV down only 0.29% at $92.95.
In this article: IJR, XLV, XBI Also: BMY, MRK, RHHBY, IBB, IMMU, LGND, QQQ, EXEL, NBIX, AMRN, ICPT, ABBV, SRPT, XNCR, LOXO, XLRN, IONS, REGN, CELG, GILD, VRTX, ASH, TSRO
Read
Inovio Spikes Higher After Positive Data Published
Article By: The Fly
Tuesday, October 2, 2018 2:17 PM EDT
Shares of Inovio are spiking higher after the company announced the publication of results in a major cancer journal, from a study of MEDI0457.
In this article: INO Also: AZN, RHHBY, REGN
Read

PARTNER HEADLINES

Latest Tweets for $REGN

No tweets yet!

$REGN

Regeneron Pharmaceuticals’ Dupixent Has Multi-Billion-Dollar Potential: Polen Capital
David J. Tanner 1/31/2018 3:55:05 AM

Note it has only been approved in Japan. And only for those whom existing treatments are ineffective. So that's a MUCH smaller market. How small I don't know. But not enough to make me bite. $REGN

1 to 1 of 1 comments